Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTC:AAWHNASDAQ:CRVSNASDAQ:GLUENASDAQ:NGNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAWHAscend Wellness$0.30-3.9%$0.35$0.27▼$1.23$60.98M1.2111,174 shs165,880 shsCRVSCorvus Pharmaceuticals$3.49+0.6%$3.45$1.75▼$10.00$237.91M0.67727,599 shs464,961 shsGLUEMonte Rosa Therapeutics$3.97-2.0%$4.59$3.21▼$12.40$244.20M1.521.06 million shs515,620 shsNGNENeurogene$17.28-4.2%$13.62$6.88▼$74.49$246.45M1.56242,255 shs110,750 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAWHAscend Wellness-3.87%-5.96%-21.33%-21.58%-74.96%CRVSCorvus Pharmaceuticals+0.58%-3.32%-1.83%-16.71%+63.08%GLUEMonte Rosa Therapeutics-1.98%-0.25%-25.52%-36.17%-5.70%NGNENeurogene-4.21%-3.95%+11.92%-0.46%-46.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAWHAscend WellnessN/AN/AN/AN/AN/AN/AN/AN/ACRVSCorvus Pharmaceuticals2.1958 of 5 stars3.51.00.00.02.62.50.6GLUEMonte Rosa Therapeutics2.1249 of 5 stars3.40.00.00.02.93.30.6NGNENeurogene2.3693 of 5 stars4.40.00.00.02.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAWHAscend Wellness 4.00Strong BuyN/AN/ACRVSCorvus Pharmaceuticals 3.00Buy$15.00329.80% UpsideGLUEMonte Rosa Therapeutics 2.75Moderate Buy$15.50290.43% UpsideNGNENeurogene 2.71Moderate Buy$44.60158.10% UpsideCurrent Analyst Ratings BreakdownLatest AAWH, NGNE, CRVS, and GLUE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025CRVSCorvus PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$12.00 ➝ $11.005/20/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$16.00 ➝ $22.005/16/2025NGNENeurogeneBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025NGNENeurogeneRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$38.00 ➝ $24.005/13/2025NGNENeurogeneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $45.005/9/2025CRVSCorvus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.00 ➝ $17.004/14/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$45.00 ➝ $16.003/26/2025CRVSCorvus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$14.00 ➝ $15.003/26/2025CRVSCorvus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/25/2025NGNENeurogeneRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$38.003/25/2025NGNENeurogeneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAWHAscend Wellness$518.59M0.12$0.04 per share6.64$0.69 per share0.43CRVSCorvus PharmaceuticalsN/AN/AN/AN/A$0.79 per shareN/AGLUEMonte Rosa Therapeutics$159.49M1.53N/AN/A$3.58 per share1.11NGNENeurogene$925K266.43N/AN/A$14.51 per share1.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAWHAscend Wellness-$48.21M-$0.40N/AN/AN/A-15.47%-72.18%-9.55%N/ACRVSCorvus Pharmaceuticals-$27.03M-$0.98N/AN/AN/AN/A-70.71%-45.90%8/5/2025 (Estimated)GLUEMonte Rosa Therapeutics-$135.35M$0.08N/AN/AN/AN/A-62.68%-38.83%N/ANGNENeurogene-$36.32M-$4.35N/AN/AN/AN/A-32.81%-27.96%8/8/2025 (Estimated)Latest AAWH, NGNE, CRVS, and GLUE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025NGNENeurogene-$1.05-$1.08-$0.03-$1.08N/AN/A5/8/2025Q1 2025CRVSCorvus Pharmaceuticals-$0.13-$0.13N/A-$0.13N/AN/A5/8/2025Q1 2025GLUEMonte Rosa Therapeutics-$0.24$0.57+$0.81$0.57$13.57 million$84.93 million3/25/2025Q4 2024CRVSCorvus Pharmaceuticals-$0.12-$0.18-$0.06-$0.18N/AN/A3/24/2025Q4 2024NGNENeurogene-$1.04-$0.99+$0.05-$0.99N/A$0.93 million3/20/2025Q4 2024GLUEMonte Rosa Therapeutics-$0.37$0.23+$0.60$0.23$43.73 million$14.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAWHAscend WellnessN/AN/AN/AN/AN/ACRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/AGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAWHAscend Wellness2.611.470.80CRVSCorvus PharmaceuticalsN/A0.920.92GLUEMonte Rosa TherapeuticsN/A6.036.03NGNENeurogeneN/A9.099.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAWHAscend Wellness17.32%CRVSCorvus Pharmaceuticals46.64%GLUEMonte Rosa Therapeutics79.96%NGNENeurogene52.37%Insider OwnershipCompanyInsider OwnershipAAWHAscend Wellness22.38%CRVSCorvus Pharmaceuticals28.50%GLUEMonte Rosa Therapeutics6.90%NGNENeurogene9.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAWHAscend Wellness2,300204.63 million166.44 millionNot OptionableCRVSCorvus Pharmaceuticals3068.17 million44.15 millionOptionableGLUEMonte Rosa Therapeutics9061.51 million57.44 millionOptionableNGNENeurogene9014.26 million13.38 millionOptionableAAWH, NGNE, CRVS, and GLUE HeadlinesRecent News About These CompaniesDeutsche Bank AG Sells 181,997 Shares of Neurogene Inc. (NASDAQ:NGNE)May 23 at 3:33 AM | marketbeat.comNeurogene (NASDAQ:NGNE) Stock Price Expected to Rise, BMO Capital Markets Analyst SaysMay 23 at 2:29 AM | americanbankingnews.com80,000 Shares in Neurogene Inc. (NASDAQ:NGNE) Bought by Vestal Point Capital LPMay 21 at 8:14 AM | marketbeat.comRaiffeisen Bank International AG Makes New Investment in Neurogene Inc. (NASDAQ:NGNE)May 20, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Invests $322,000 in Neurogene Inc. (NASDAQ:NGNE)May 20, 2025 | marketbeat.comNeurogene (NASDAQ:NGNE) Stock Rating Lowered by Baird R WMay 19, 2025 | marketbeat.comNeurogene Inc. (NASDAQ:NGNE) Receives $46.20 Average Price Target from BrokeragesMay 19, 2025 | americanbankingnews.comRTW Investments LP Purchases 215,000 Shares of Neurogene Inc. (NASDAQ:NGNE)May 18, 2025 | marketbeat.comNeurogene (NASDAQ:NGNE) Cut to "Neutral" at Robert W. BairdMay 18, 2025 | americanbankingnews.comNeurogene (NASDAQ:NGNE) Rating Lowered to "Hold" at Baird R WMay 18, 2025 | americanbankingnews.comBaird Downgrades Neurogene (NGNE)May 16, 2025 | msn.comNeurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAVMay 16, 2025 | finance.yahoo.comStuart Cobb Sells 6,797 Shares of Neurogene Inc. (NASDAQ:NGNE) StockMay 16, 2025 | insidertrades.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $748,000 Position in Neurogene Inc. (NASDAQ:NGNE)May 16, 2025 | marketbeat.comNeurogene Inc. (NASDAQ:NGNE) Given Average Recommendation of "Buy" by AnalystsMay 16, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Sells 23,477 Shares of Neurogene Inc. (NASDAQ:NGNE)May 16, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for Neurogene Q2 Earnings?May 16, 2025 | americanbankingnews.comNeurogene (NASDAQ:NGNE) Given New $45.00 Price Target at HC WainwrightMay 15, 2025 | marketbeat.comOctagon Capital Advisors LP Increases Stake in Neurogene Inc. (NASDAQ:NGNE)May 15, 2025 | marketbeat.comDriehaus Capital Management LLC Sells 69,422 Shares of Neurogene Inc. (NASDAQ:NGNE)May 13, 2025 | marketbeat.comNeurogene (NASDAQ:NGNE) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPSMay 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAAWH, NGNE, CRVS, and GLUE Company DescriptionsAscend Wellness OTC:AAWH$0.30 -0.01 (-3.87%) As of 05/23/2025 03:59 PM EasternAscend Wellness Holdings, Inc. engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States. The company offers flower, pre-rolls, concentrates, vapes, edibles, tinctures, and other cannabis-related products under the Common Goods, SimplyHerb, Ozone, Ozone Reserve, Royale, Tunnel Vision, Miss Grass, Lowell Smokes, Edie Parker, 1906, and AiroPro brands. It also owns, operates, and manages cannabis cultivation facilities and dispensaries. The company sells its products through company-owned retail stores and third-party licensed retail cannabis stores. Ascend Wellness Holdings, Inc. was incorporated in 2018 and is headquartered in New York, New York.Corvus Pharmaceuticals NASDAQ:CRVS$3.49 +0.02 (+0.58%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.49 0.00 (0.00%) As of 05/23/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Monte Rosa Therapeutics NASDAQ:GLUE$3.97 -0.08 (-1.98%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.96 -0.01 (-0.25%) As of 05/23/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Neurogene NASDAQ:NGNE$17.28 -0.76 (-4.21%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$18.35 +1.07 (+6.19%) As of 05/23/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
